21/02/2026
🔥 Blindness is now the #2 reason people are suing some GLP-1 manufacturers. (Stomach Paralysis is #1)
GLP-1 medications, or glucagon-like peptide-1 receptor agonists, are a class of drugs primarily used to manage type 2 diabetes by mimicking the GLP-1 hormone to regulate blood sugar. They're also widely prescribed for weight loss due to their appetite-suppressing effects.
Common Examples: Popular GLP-1 drugs include semaglutide (Ozempic for diabetes, Wegovy for weight loss), liraglutide (Victoza for diabetes, Saxenda for weight loss), dulaglutide (Trulicity), and exenatide (Byetta, Bydureon).
Some, like tirzepatide (Mounjaro), act on both GLP-1 and GIP receptors for enhanced effects on blood sugar and weight.
Higher-dose versions like Wegovy are FDA-approved specifically for chronic weight management in obesity.
How They Work: These injectables (weekly or daily) boost insulin release, slow digestion, and signal fullness to the brain, lowering A1C levels and promoting 8-15% body weight loss in trials.
They're often paired with diet and exercise; stopping them typically leads to weight regain.
“A federal panel of judges agreed to centralize litigation against manufacturers of GLP-1 drugs, alleging that they have caused non-arteritic anterior ischemic optic neuropathy (NAION). This is the second-highest category for lawsuits against GLP-1 manufacturers behind gastroparesis, also known as stomach paralysis. This comes as HHS recently announced it is working to expand access to the medications as part of the response to the ongoing obesity epidemic in the United States, where over 40% of American adults are obese.
A 2025 study of 139,000 diabetes patients over the age of 66 found that those who received GLP-1 drugs for the treatment of diabetes were twice as likely to develop neovascular age-related macular degeneration (nAMD) than the control group. Another 2025 study concluded users of GLP-1 drugs were 68.6 times more likely to develop NAION and eight times more likely to develop diabetic retinopathy than those taking empagliflozin, exenatide, insulin, or metformin.” - Credit: The Highwire
- Dr. Doug Corrigan